5-HT2 Receptor Modulators for Cardiovascular Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmacological agents for treating cardiovascular diseases such as heart failure and cardiac hypertrophy have severe shortcomings, including adverse effects and limited efficacy, particularly in severe cases, necessitating the development of new, safe, and effective therapeutic modalities.
Innovation Solution
Development of compounds that bind to and modulate 5-hydroxytryptamine (5-HT2) receptors, which are cardioprotective and capable of regulating non-cardiac muscle cell growth, to address the underlying molecular mechanisms of cardiovascular and muscular conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current pharmacological agents are used to treat cardiovascular diseases, then some therapeutic effect is achieved, but severe adverse effects and limited efficacy occur
Solution Approach 1:
The patent applies parameter changes by modifying the pharmacological target from conventional receptors to 5-HT2A serotonin receptors. This fundamental parameter change in the molecular target enables selective blockade of pathological signaling pathways (such as those involving beta-arrestin and transcriptional regulation) while preserving beneficial cardiovascular functions, thereby achieving therapeutic efficacy with reduced adverse effects
Solution Approach 2:
The patent employs beta-arrestin as an intermediary mechanism in the therapeutic action. By targeting the interaction between 5-HT2A receptors and beta-arrestin, the compounds selectively interfere with harmful signaling pathways that lead to cardiovascular disease progression, while allowing other essential signaling pathways to function normally, thus resolving the contradiction between efficacy and adverse effects
2Ease of operation
If conventional treatments are used for heart failure and cardiac hypertrophy, then symptomatic relief is provided, but underlying molecular mechanisms are not addressed
Solution Approach 1:
The patent applies preliminary action by blocking 5-HT2A receptor signaling pathways before they can trigger the cascade of molecular events leading to cardiac hypertrophy and heart failure. By preventing the activation of downstream pathways (including those involving CREB, NF-κB, and other transcription factors), the compounds address the underlying molecular mechanisms proactively, rather than merely responding to established symptoms
Solution Approach 2:
The patent extracts and targets the specific pathological signaling pathway involving 5-HT2A receptors and beta-arrestin from the complex network of cardiovascular signaling. By selectively interfering with this specific pathway while leaving other essential cardiovascular signaling intact, the treatment addresses underlying mechanisms without disrupting overall cardiac function
Data Source
AI summary
The present invention provides certain compounds, pharmaceutical formulations thereof, and methods for the treatment of conditions mediated by 5-HT2 receptors. These compounds provide for modulation of the signals mediated by 5-HT2 receptors, specifically those receptors in the cardiovascular system. Thus, these compounds may be used alone or in conjunction with other drugs to treat cardiovascular diseases such as, but not limited to, muscle atrophy, cardiac hypertrophy, heart failure, and primary pulmonary hypertension.